^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) +
    fimepinostat (CUDC-907) (PI3K inhibitor, HDAC inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Br J Cancer
    Title:

    The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML

    Published date:
    06/07/2021
    Excerpt:
    ...gilteritinib and CUDC-907, a dual inhibitor of PI3K and histone deacetylases, synergistically induce apoptosis in FLT3-ITD AML cell lines and primary patient samples and have striking in vivo efficacy….CUDC-907 plus gilteritinib shows synergistic antileukemic activity against FLT3-ITD AML in vitro and in vivo, demonstrating strong translational therapeutic potential.
    DOI:
    https://doi.org/10.1038/s41408-021-00502-7
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

    Published date:
    11/06/2019
    Excerpt:
    CUDC-907 and gilteritinib demonstrated potent synergistic antileukemic effects in FLT3-ITD AML cell lines in vitro and patient samples ex vivo, with combined therapy.
    DOI:
    10.1182/blood-2019-123793